Review



tsg101  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Proteintech tsg101
    Identification and angiogenesis of exos from BA-pretreated BMSCs (A) The morphology of BMSC-exos and BA-BMSC-exos under transmission electron microscopy. (B) Nanoparticle tracking analysis showing the size distribution of BMSC-exos and BA-BMSC-exos. (C) The expression levels of the exosome markers CD9, <t>TSG101,</t> and CD81 were measured by western blot. (D) The uptake of BA-BMSC-exos by HUVECs was detected by immunofluorescence staining (scale bar: 100 μm). (E) CCK8 determined the viability of HUVECs after treatment with exos. (F) Cell migration of HUVECs determined by Transwell assay (scale bar: 100 μm). (G) Tube formation of HUVECs following treatment with exos (scale bar: 100 μm). The expression of VEGF and CD31 in HUVECs was determined by (H) Western blot and (I) qPCR. Data are presented as mean ± standard deviation (SD), n = 3, p -values are calculated using one-way or two-way ANOVA, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.
    Tsg101, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 820 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tsg101/product/Proteintech
    Average 96 stars, based on 820 article reviews
    tsg101 - by Bioz Stars, 2026-02
    96/100 stars

    Images

    1) Product Images from "3D-printed scaffold loaded with baicalin exosomes promotes bone defect repair via mediating PRRX2 to alleviate inflammation"

    Article Title: 3D-printed scaffold loaded with baicalin exosomes promotes bone defect repair via mediating PRRX2 to alleviate inflammation

    Journal: iScience

    doi: 10.1016/j.isci.2025.113565

    Identification and angiogenesis of exos from BA-pretreated BMSCs (A) The morphology of BMSC-exos and BA-BMSC-exos under transmission electron microscopy. (B) Nanoparticle tracking analysis showing the size distribution of BMSC-exos and BA-BMSC-exos. (C) The expression levels of the exosome markers CD9, TSG101, and CD81 were measured by western blot. (D) The uptake of BA-BMSC-exos by HUVECs was detected by immunofluorescence staining (scale bar: 100 μm). (E) CCK8 determined the viability of HUVECs after treatment with exos. (F) Cell migration of HUVECs determined by Transwell assay (scale bar: 100 μm). (G) Tube formation of HUVECs following treatment with exos (scale bar: 100 μm). The expression of VEGF and CD31 in HUVECs was determined by (H) Western blot and (I) qPCR. Data are presented as mean ± standard deviation (SD), n = 3, p -values are calculated using one-way or two-way ANOVA, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.
    Figure Legend Snippet: Identification and angiogenesis of exos from BA-pretreated BMSCs (A) The morphology of BMSC-exos and BA-BMSC-exos under transmission electron microscopy. (B) Nanoparticle tracking analysis showing the size distribution of BMSC-exos and BA-BMSC-exos. (C) The expression levels of the exosome markers CD9, TSG101, and CD81 were measured by western blot. (D) The uptake of BA-BMSC-exos by HUVECs was detected by immunofluorescence staining (scale bar: 100 μm). (E) CCK8 determined the viability of HUVECs after treatment with exos. (F) Cell migration of HUVECs determined by Transwell assay (scale bar: 100 μm). (G) Tube formation of HUVECs following treatment with exos (scale bar: 100 μm). The expression of VEGF and CD31 in HUVECs was determined by (H) Western blot and (I) qPCR. Data are presented as mean ± standard deviation (SD), n = 3, p -values are calculated using one-way or two-way ANOVA, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.

    Techniques Used: Transmission Assay, Electron Microscopy, Expressing, Western Blot, Immunofluorescence, Staining, Migration, Transwell Assay, Standard Deviation



    Similar Products

    tsg101  (Bioss)
    94
    Bioss tsg101
    Tsg101, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tsg101/product/Bioss
    Average 94 stars, based on 1 article reviews
    tsg101 - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    tsg101  (Proteintech)
    96
    Proteintech tsg101
    Identification and angiogenesis of exos from BA-pretreated BMSCs (A) The morphology of BMSC-exos and BA-BMSC-exos under transmission electron microscopy. (B) Nanoparticle tracking analysis showing the size distribution of BMSC-exos and BA-BMSC-exos. (C) The expression levels of the exosome markers CD9, <t>TSG101,</t> and CD81 were measured by western blot. (D) The uptake of BA-BMSC-exos by HUVECs was detected by immunofluorescence staining (scale bar: 100 μm). (E) CCK8 determined the viability of HUVECs after treatment with exos. (F) Cell migration of HUVECs determined by Transwell assay (scale bar: 100 μm). (G) Tube formation of HUVECs following treatment with exos (scale bar: 100 μm). The expression of VEGF and CD31 in HUVECs was determined by (H) Western blot and (I) qPCR. Data are presented as mean ± standard deviation (SD), n = 3, p -values are calculated using one-way or two-way ANOVA, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.
    Tsg101, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tsg101/product/Proteintech
    Average 96 stars, based on 1 article reviews
    tsg101 - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier
    anti tsg101  (Proteintech)
    96
    Proteintech anti tsg101
    Identification and angiogenesis of exos from BA-pretreated BMSCs (A) The morphology of BMSC-exos and BA-BMSC-exos under transmission electron microscopy. (B) Nanoparticle tracking analysis showing the size distribution of BMSC-exos and BA-BMSC-exos. (C) The expression levels of the exosome markers CD9, <t>TSG101,</t> and CD81 were measured by western blot. (D) The uptake of BA-BMSC-exos by HUVECs was detected by immunofluorescence staining (scale bar: 100 μm). (E) CCK8 determined the viability of HUVECs after treatment with exos. (F) Cell migration of HUVECs determined by Transwell assay (scale bar: 100 μm). (G) Tube formation of HUVECs following treatment with exos (scale bar: 100 μm). The expression of VEGF and CD31 in HUVECs was determined by (H) Western blot and (I) qPCR. Data are presented as mean ± standard deviation (SD), n = 3, p -values are calculated using one-way or two-way ANOVA, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.
    Anti Tsg101, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti tsg101/product/Proteintech
    Average 96 stars, based on 1 article reviews
    anti tsg101 - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier
    tsg01  (Proteintech)
    96
    Proteintech tsg01
    Identification and angiogenesis of exos from BA-pretreated BMSCs (A) The morphology of BMSC-exos and BA-BMSC-exos under transmission electron microscopy. (B) Nanoparticle tracking analysis showing the size distribution of BMSC-exos and BA-BMSC-exos. (C) The expression levels of the exosome markers CD9, <t>TSG101,</t> and CD81 were measured by western blot. (D) The uptake of BA-BMSC-exos by HUVECs was detected by immunofluorescence staining (scale bar: 100 μm). (E) CCK8 determined the viability of HUVECs after treatment with exos. (F) Cell migration of HUVECs determined by Transwell assay (scale bar: 100 μm). (G) Tube formation of HUVECs following treatment with exos (scale bar: 100 μm). The expression of VEGF and CD31 in HUVECs was determined by (H) Western blot and (I) qPCR. Data are presented as mean ± standard deviation (SD), n = 3, p -values are calculated using one-way or two-way ANOVA, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.
    Tsg01, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tsg01/product/Proteintech
    Average 96 stars, based on 1 article reviews
    tsg01 - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier
    tumor susceptibility gene 101  (Proteintech)
    96
    Proteintech tumor susceptibility gene 101
    Identification and angiogenesis of exos from BA-pretreated BMSCs (A) The morphology of BMSC-exos and BA-BMSC-exos under transmission electron microscopy. (B) Nanoparticle tracking analysis showing the size distribution of BMSC-exos and BA-BMSC-exos. (C) The expression levels of the exosome markers CD9, <t>TSG101,</t> and CD81 were measured by western blot. (D) The uptake of BA-BMSC-exos by HUVECs was detected by immunofluorescence staining (scale bar: 100 μm). (E) CCK8 determined the viability of HUVECs after treatment with exos. (F) Cell migration of HUVECs determined by Transwell assay (scale bar: 100 μm). (G) Tube formation of HUVECs following treatment with exos (scale bar: 100 μm). The expression of VEGF and CD31 in HUVECs was determined by (H) Western blot and (I) qPCR. Data are presented as mean ± standard deviation (SD), n = 3, p -values are calculated using one-way or two-way ANOVA, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.
    Tumor Susceptibility Gene 101, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tumor susceptibility gene 101/product/Proteintech
    Average 96 stars, based on 1 article reviews
    tumor susceptibility gene 101 - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    Identification and angiogenesis of exos from BA-pretreated BMSCs (A) The morphology of BMSC-exos and BA-BMSC-exos under transmission electron microscopy. (B) Nanoparticle tracking analysis showing the size distribution of BMSC-exos and BA-BMSC-exos. (C) The expression levels of the exosome markers CD9, TSG101, and CD81 were measured by western blot. (D) The uptake of BA-BMSC-exos by HUVECs was detected by immunofluorescence staining (scale bar: 100 μm). (E) CCK8 determined the viability of HUVECs after treatment with exos. (F) Cell migration of HUVECs determined by Transwell assay (scale bar: 100 μm). (G) Tube formation of HUVECs following treatment with exos (scale bar: 100 μm). The expression of VEGF and CD31 in HUVECs was determined by (H) Western blot and (I) qPCR. Data are presented as mean ± standard deviation (SD), n = 3, p -values are calculated using one-way or two-way ANOVA, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.

    Journal: iScience

    Article Title: 3D-printed scaffold loaded with baicalin exosomes promotes bone defect repair via mediating PRRX2 to alleviate inflammation

    doi: 10.1016/j.isci.2025.113565

    Figure Lengend Snippet: Identification and angiogenesis of exos from BA-pretreated BMSCs (A) The morphology of BMSC-exos and BA-BMSC-exos under transmission electron microscopy. (B) Nanoparticle tracking analysis showing the size distribution of BMSC-exos and BA-BMSC-exos. (C) The expression levels of the exosome markers CD9, TSG101, and CD81 were measured by western blot. (D) The uptake of BA-BMSC-exos by HUVECs was detected by immunofluorescence staining (scale bar: 100 μm). (E) CCK8 determined the viability of HUVECs after treatment with exos. (F) Cell migration of HUVECs determined by Transwell assay (scale bar: 100 μm). (G) Tube formation of HUVECs following treatment with exos (scale bar: 100 μm). The expression of VEGF and CD31 in HUVECs was determined by (H) Western blot and (I) qPCR. Data are presented as mean ± standard deviation (SD), n = 3, p -values are calculated using one-way or two-way ANOVA, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.

    Article Snippet: After washing three times, the membranes were stained with primary antibodies against CD9, TSG101, CD31, p -AKT, AKT, IL-6, IL-1β, TNF-α, Nrf2, and HO-1 (all from Abcam, UK), vascular endothelial growth factor (VEGF) (from Proteintech, USA) overnight at 4 °C.

    Techniques: Transmission Assay, Electron Microscopy, Expressing, Western Blot, Immunofluorescence, Staining, Migration, Transwell Assay, Standard Deviation